The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products.
Teva Pharmaceutical Industries hasn't had much good news to share lately. Today, it had a little something to crow about: The FDA has granted orphan status to its cancer-fighting drug, Treanda.
The allegations in a recently released lawsuit against Cephalon suggest that company was particularly obscene about pushing off-label uses, because at the time it was operating under a Corporate Integrity Agreement forged after getting caught for similar problems a few years earlier.
Boosted by an intriguing backstory tied to the Cold War, a study showing Teva Pharmaceutical's Treanda worked better on patients with non-Hodgkin lymphomas and produced fewer side effects, is getting lots of attention at ASCO.
Lundbeck's CFO Anders Gotzsche emphasized the prospects of drugs such as Selincro for alcohol dependence, the experimental antidepressant Lu AA21004 in late-stage development and a long-lasting formulation of Abilify.
Teva Pharmaceutical Industries' ($TEVA) Cephalon has recalled one lot of leukemia drug Treanda after glass fragments were found in one of the vials. FDA-approved labeling for Treanda states that...
The Justice Department isn't just interested in Cephalon's Treanda operations. It's also looking at the drugmaker's wakefulness meds Nuvigil and Provigil. Cephalon ($CEPH) said the feds issued a
Cephalon has received another query from the feds. As Pharmalot reports, the company disclosed a subpoena from the U.S. Attorney's Office in New York, requesting information about the company's
Yet another drugmaker finds itself under the U.S. Justice Department microscope. As Pharmalot reports, Cephalon ($CEPH) has received some requests from the feds for documents relating to potential
Cephalon could have a blockbuster on its hands following the release of new data about its tumor-fighting therapy Treanda. The drug is currently approved for a form of non-Hodgkin lymphoma, which